6562 logo

UBI Pharma TPEX:6562 Stock Report

Last Price

NT$14.25

Market Cap

NT$1.7b

7D

1.8%

1Y

-62.3%

Updated

12 May, 2024

Data

Company Financials

6562 Stock Overview

UBI Pharma Inc. develops, manufactures, and sells pharmaceutical products in Taiwan.

6562 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance2/6
Financial Health4/6
Dividends0/6

UBI Pharma Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for UBI Pharma
Historical stock prices
Current Share PriceNT$14.25
52 Week HighNT$42.54
52 Week LowNT$10.00
Beta0.19
1 Month Change-49.29%
3 Month Change-56.02%
1 Year Change-62.32%
3 Year Changen/a
5 Year Change-37.75%
Change since IPO-85.19%

Recent News & Updates

Recent updates

Shareholder Returns

6562TW BiotechsTW Market
7D1.8%4.5%3.0%
1Y-62.3%-4.7%27.9%

Return vs Industry: 6562 underperformed the TW Biotechs industry which returned -18.2% over the past year.

Return vs Market: 6562 underperformed the TW Market which returned 31.7% over the past year.

Price Volatility

Is 6562's price volatile compared to industry and market?
6562 volatility
6562 Average Weekly Movement11.3%
Biotechs Industry Average Movement4.9%
Market Average Movement4.7%
10% most volatile stocks in TW Market8.5%
10% least volatile stocks in TW Market2.3%

Stable Share Price: 6562's share price has been volatile over the past 3 months.

Volatility Over Time: 6562's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of TW stocks.

About the Company

FoundedEmployeesCEOWebsite
2014n/aChei-Hsiang Chenwww.ubi-pharma.com

UBI Pharma Inc. develops, manufactures, and sells pharmaceutical products in Taiwan. The company offers protein drugs and formulations of molecule products; and develops biobetters and specialty injectables. Its product portfolio includes film coated, Virapine, and Efanzy tablets, as well as Terbutaline; and Levetir concentrate solution for infusion.

UBI Pharma Inc. Fundamentals Summary

How do UBI Pharma's earnings and revenue compare to its market cap?
6562 fundamental statistics
Market capNT$1.68b
Earnings (TTM)NT$803.00k
Revenue (TTM)NT$648.63m

2,097x

P/E Ratio

2.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6562 income statement (TTM)
RevenueNT$648.63m
Cost of RevenueNT$451.50m
Gross ProfitNT$197.12m
Other ExpensesNT$196.32m
EarningsNT$803.00k

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)0.0068
Gross Margin30.39%
Net Profit Margin0.12%
Debt/Equity Ratio7.9%

How did 6562 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.